- Pentadecapeptide BPC 157 and the central nervous system - Preclinical safety evaluation of body protective compound-157
These advanced peptide formulations are produced through an exclusive clinical partnership with Cellgenica global leader in regenerative medicine innovation with over a decade of expertise in peptide science
The obesity Phase 3 studies and the first topline readout The obesity backbone includes 76-week efficacy-and-safety trials in adults with overweight or obesity without type 2 diabetes (SYNCHRONIZE-1, NCT06066515) and with type 2 diabetes (SYNCHRONIZE-2, NCT06066528), plus region-specific studies
The archaeon MhTyrA from clade II preferred PDH over ADH activity (Figure 3C) and had a non-acidic residue at the 222 position (Figure 2, Figure S1)
Drugs Medication, without carrier or peptidase inhibitor, included stable gastric pentadecapeptide BPC-157 (a partial sequence of the human gastric juice protein BPC, freely soluble in water at pH 7.0 and in saline)
What are the potential side effects of DSIP
